Form 4: Kymera Therapeutics CFO Exercises Stock Options
SEC Form 4 Filing
Bruce N. Jacobs, CFO of Kymera Therapeutics, exercised stock options to acquire 25,000 shares of common stock at $2.08 per share on March 31, 2025.
Summary
- On March 31, 2025, Bruce N. Jacobs, the Chief Financial Officer of Kymera Therapeutics, exercised stock options.
- This transaction involved the acquisition of 25,000 shares of Kymera Therapeutics' common stock at a price of $2.08 per share.
- Following this transaction, Jacobs directly owns 226,886 shares of common stock.
- Jacobs also holds options for 69,899 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard SEC filing regarding stock option exercise.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction may have a minor dilutive effect on existing shareholders due to the issuance of new shares.
Key Dates
| Date | Description |
|---|---|
| July 1, 2020 | 25% of the shares underlying the stock option vested. |
| August 28, 2029 | Expiration date of the stock options. |
| 03/31/2025 | Date of the transaction where stock options were exercised. |
| 04/01/2025 | Date of signature on the Form 4 filing. |
Keywords
Kymera Therapeutics, Bruce N. Jacobs, stock options, Form 4, CFO, KYMR, securities, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.